Eigen Therapeutics

Eigen Therapeutics specializes in developing "priming therapies" that upregulate specific antigens in cancer cells to improve the effectiveness of antigen-directed treatments (e.g., ADCs; antibody-drug conjugates). The problem being solved is tumor heterogeneity. Antigen-directed cancer therapies, ADCs and radioligand therapies (RLTs), sometimes fail in patients due to the heterogeneous expression of the target that they're designed to bind. Eigen's proprietary software + robotics platform identifies compounds with the potential to increase the expression of the receptors targeted by Antigen-directed cancer therapies, which improves the probability cancer cells express these receptors. The result is improved efficacy and reduced dosing required to elicit a response, improving safety. Eigen's lead primer demonstrates a 2x increase in a receptor of interest leading to a 20x increase in the cancer-killing ability of the associated antigen-directed therapy.